All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Verastem Oncology’s combo shows two-year durability in ovarian cancer

Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during…
Spinogenix’s Fragile X Syndrome drug shows normalisation of brain function

Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, suggesting a normalisation of…
UK launches programme to improve dementia clinical trial enrolment

An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has…
Sanofi’s bispecific scores in respiratory diseases but fails in eczema

Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic…
Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD

Alar Pharmaceuticals’ long-acting, ketamine-based therapy has shown early signs of symptom improvement in treatment-resistant depression (TRD) in a Phase I…

Data shows 6.7% of global clinical trials impacted by Middle East disruption

An analysis of 65,061 globally recruiting clinical trials across 186 countries finds that 4,361 studies, equivalent to 6.7% of all…
Oric to advance prostate cancer drug to Phase III trials

ORIC Pharmaceuticals will advance its prostate cancer drug to Phase III trials after it showed survival benefit in a Phase…
MSD boasts data for oral PCSK9 inhibitor as add on therapy

MSD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has reduced low-density lipoprotein cholesterol (LDL-C) levels when combined with background…
Viridian Therapeutics’ stock sinks despite positive Phase III TED data

Viridian Therapeutics stock has fallen by 38%, despite its active thyroid eye disease (TED) drug meeting the primary endpoints of…
Wave’s stock crashes 50% on Phase I obesity data

Wave Life Sciences’ stock has crashed by nearly 50% after its Phase I obesity trial showed low levels of weight…